Needham Reiterates Buy on Stoke Therapeutics, Maintains $25 Price Target
Portfolio Pulse from richadhand@benzinga.com
Needham analyst Joseph Stringer reiterated a Buy rating on Stoke Therapeutics (NASDAQ:STOK) and maintained a $25 price target.
June 26, 2023 | 11:07 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Joseph Stringer reiterated a Buy rating on Stoke Therapeutics (NASDAQ:STOK) and maintained a $25 price target.
The reiteration of the Buy rating and maintenance of the $25 price target by Needham analyst Joseph Stringer indicates a positive outlook for Stoke Therapeutics. This could lead to increased investor confidence and a potential short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100